{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089897","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.208164+00:00","generated_at":"2026-06-11T16:31:25.992926+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Onconova reports Q2 2023 net loss of $4.3M; cash $29.7M; pipeline updates for narazaciclib and rigosertib","bullets":["Net loss of $4.3M ($0.20 per share) vs $4.0M ($0.19) in Q2 2022.","Cash $29.7M as of June 30, 2023; sufficient into Q2 2024.","Topline results from Phase 1/2 narazaciclib studies expected in Q4 2023.","Plans registrational trial for rigosertib in RDEB-SCC after constructive FDA Type B meeting in June.","R&D expense $2.5M, G&A $2.2M for Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089897","json":"https://secwatch.observer/filing/0001104659-23-089897.json","markdown":"https://secwatch.observer/filing/0001104659-23-089897.md","text":"https://secwatch.observer/filing/0001104659-23-089897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923089897/0001104659-23-089897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923089897/tm2323468d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T16:31:25.992926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac6b0180918396156512664e014b6e06ed0ccf80","claim":"Traws Pharma, Inc. reported the quarter and six months ended June 30, 2023 results: net income $4.3 million, EPS $0.20 per share.","evidence_excerpt":"Net loss for the second quarter of 2023 was $4.3 million, or $0.20 per share on 21.0 million weighted shares outstanding, compared with a net loss of $4.0 million, or $0.19 per share for the second quarter of 2022 on 20.9 million weighted shares outstanding.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923089897/0001104659-23-089897-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and six months ended June 30, 2023"},{"label":"Net income","value":"$4.3 million"},{"label":"EPS","value":"$0.20 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}